27 Aug 2026 (Navroze Bureau) : The upcoming European Society of Cardiology (ESC) Congress is set to put several major questions in cardiovascular medicine under the spotlight, including the use of statins in older adults and emerging treatments for patients recovering from heart attacks.
The discussions are expected to focus on how new evidence could influence treatment decisions for high-risk and ageing populations.
Statins in Older Adults Under Review
One major area of interest will be whether older adults should routinely receive statin therapy to prevent cardiovascular events.
Statins lower LDL cholesterol and are widely used to reduce the risk of heart attacks and strokes. However, treatment decisions become more complex with age because doctors must consider frailty, other illnesses, medication interactions and life expectancy.
Balancing Benefits and Risks
For elderly patients, the potential cardiovascular benefits of lowering cholesterol need to be weighed against individual health circumstances.
Researchers and cardiologists are expected to examine evidence on whether starting or continuing statins in older adults provides meaningful protection, particularly for people who have never previously experienced a cardiovascular event.
New Therapies After Heart Attack
Another key focus at the ESC meeting will be emerging therapies designed to improve recovery after a heart attack.
Despite advances in emergency treatment, patients who survive myocardial infarction can remain at risk of heart failure, abnormal heart rhythms and another cardiovascular event.
New approaches are being investigated to reduce these risks and improve long-term outcomes.
Targeting Heart Failure Risk
Some of the latest cardiovascular research is examining treatments that could protect the heart after an acute myocardial infarction.
The goal is to limit further damage, improve cardiac function and reduce the likelihood of patients developing chronic heart failure.
Personalised Cardiovascular Care
The discussions also reflect a wider shift toward more individualised cardiovascular treatment.
Rather than applying identical therapies to every patient, clinicians increasingly consider factors such as age, underlying disease, cardiovascular risk, kidney function, other medications and previous medical history when selecting treatments.
Why ESC Matters
The ESC Congress is one of the world’s major cardiovascular medical meetings, bringing together cardiologists and researchers to discuss clinical trials, guidelines and advances in heart care.
New research presented at the meeting can influence future clinical practice and help identify areas where existing treatment strategies may need to change.